In the News & Media.
In the News
- Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo
Fierce Biotech - May 5, 2025 - Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1 Negative HNSCC
OncLive - May 5, 2025 - Unlocking the potential to better target cancer with immunotherapy
EurekAlert | AAAS - December 13, 2024 - Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC
OncLive - November 14, 2024 - Immutep announces positive results in head and neck cancer treatment
Finance News Network - September 23, 2024 - Immutep's CEO Marc Voigt reports first subject dosed in autoimmune disease study
Finance News Network - August 19, 2024 - Clinical trials in cancer and autoimmune diseases: Immutep's CEO Marc Voigt provides an update
Finance News Network - July 30, 2024 - Insights from ASCO 2024! Dr Frederic Forget from Centre Hospitalier de l’Ardennes presents the AIPAC-003 study on eftilagimod alpha (efti) in breast cancer
MediMix Oncology - July 16, 2024 - New Immunotherapy Combination Effective in Head & Neck Cancer
Targeted Oncology - July 12, 2024 - First-Line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1-Negative HNSCC
OncLive - July 11, 2024 - Immutep (ASX:IMM) TACTI-003 results, June 2024
Finance News Network - June 27, 2024 - Healthcare opportunities amid market challenges
Financial Review - May 15, 2024 - Immutep's exciting early results from Phase 2 trial on soft tissue sarcoma
The Australian, Business Review - May 2, 2024 - Eftilagimod Alpha-Based Triplet is Well Tolerated, Generates Responses in Soft Tissue Sarcoma
OncLive - May 2, 2024 - Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC
OncLive - April 24, 2024 - Encouraging results for Immutep's cancer therapies
Finance News Network - March 25, 2024 - Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer
OncLive - March 7, 2024 - Bell Potter's top stock picks for 2024
Livewire - December 18, 2023 - “LAG Time” Promising First-Line Treatment for Metastatic NSCLC
Physician's Weekly - November 2, 2023 - Immutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy
Finance News Network - October 31, 2023 - Q&A: Immutep's CEO on improving lung cancer survival, and where to next after trial success
Stockhead - October 26, 2023 - ESMO 2023: Immutep’s LAG-3 immunotherapy shows 35.5 months overall survival in NSCLC
BioWorld - October 24, 2023 - Immutep touts mid-stage data for LAG-3 drug in first-line NSCLC, finalizing plans for PhIII test: #ESMO23
Endpoints News - October 24, 2023 - Perennial fundie’s top small-cap healthcare picks
Financial Review - October 19, 2023 - TACTI-002 Data Show Antitumor Activity With Second-Line Eftilagimod Alpha and PD-1 Inhibition in HNSCC
OncLive - September 1, 2023 - Immunotherapy is Here to Stay
Drug Discovery World - July 25, 2023 - Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer
OncLive - July 5, 2023 - Ramsay boasts M&A appeal despite failed KKR bid
Financial Review - June 29, 2023 - Immutep picks up more funds for LAG-3 oncology and autoimmune studies
Endpoints News - June 28, 2023 - First-line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefit in PD-L1+ NSCLC
OncLive - May 17, 2023 - Immunotherapy for Cancer: A Look Back and A Look Ahead
Genetic Engineering & Biotechnology News: GEN - May 3, 2023 - Soluble LAG-3 Protein Plus Pembrolizumab Shows Activity in PD-1 Resistant NSCLC
Targeted Oncology - April 3, 2023 - PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
OncLive – February 6, 2023 - Eftilagimod Alpha Combination Demonstrates Durable Responses in Frontline NSCLC
Targeted Therapies in Oncology - January 18, 2023 - Soluble LAG3 Primes T Cells to Attack NSCLC
Cancer Discovery - News in Brief - January 9, 2023 - Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions
Levine Media Group - December 22, 2022 - Investigators Look to Translate Positive Results of Eftilagimod Alpha Combination to NSCLC
OncLive – November 22, 2022 - The Journey Has Just Begun For LAG-3 Therapeutics
In Vivo – November 21, 2022 - Immutep’s LAG-3 efti, with pembrolizumab, meets primary endpoint in first-line NSCLC
BioWorld – November 15, 2022 - SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting
SITC - November 3, 2022 - Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches
BioSpace – September 14, 2022 - Eftilagimod Alpha/Pembrolizumab Combo Elicits Encouraging Survival Benefits in Anti–PD-1/PD-L1 Refractory NSCLC
OncLive – August 2, 2022 - Efti, Pembrolizumab Doublet Continues to Impress in Metastatic NSCLC
MedPage Today – July 6, 2022 - LAG-3 Fills a Complex Role in the Immune System
OncLive – July 27, 2022 - How Immutep and other immunotherapy biotechs have changed cancer treatment
The Australian – June 2, 2022 - LAG-3 Pioneer Discusses BMS Milestone and Potential of the New Checkpoint
BioSpace – April 26, 2022